Butyrogenic bacteria after acute graft-versus-host disease (GVHD) are associated with the development of steroid-refractory GVHD

Blood Adv. 2019 Oct 8;3(19):2866-2869. doi: 10.1182/bloodadvances.2019000362.

Jonathan L Golob¹, Martha M DeMeules², Tillie Loeffelholz², Z Z Quinn², Michael K Dame³, Sabrina S Silvestri³, Michael C Wu⁴, Thomas M Schmidt¹, Tina L Fiedler², Matthew J Hoostal¹, Marco Mielcarek^{5

6}, Jason Spence^{3

7

8}, Steven A Pergam^{2

5

9}, David N Fredricks^{2

5

9}

¹ Division of Infectious Diseases, Department of Medicine, University of Michigan, Ann Arbor, MI.
² Infectious Disease Sciences, Vaccines and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA.
³ Department of Internal Medicine, University of Michigan, Ann Arbor, MI.
⁴ Public Health Sciences Division and.
⁵ Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.
⁶ Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA.
⁷ Department of Cell and Developmental Biology, University of Michigan, Ann Arbor, MI.
⁸ Department of Biomedical Engineering, University of Michigan College of Engineering, Ann Arbor, MI; and.
⁹ Division of Allergy & Infectious Diseases, Department of Medicine, University of Washington, Seattle, WA.

Abstract

The presence of butyrogenic bacteria after the onset of acute GVHD associates with subsequent steroid-refractory GVHD or chronic GVHD.
Butyrate inhibits human colonic stem cells from forming an intact epithelial monolayer.